Sheffield Motor Neurone Disorders Care and Research Centre

University of Sheffield

The Sheffield Motor Neurone Disorders clinic offers multi-disciplinary care and support to patients and carers living with Motor Neurone Disorders (MND).

There is a dedicated team who aim to provide a high level of care and support to people living with MND. We are a regional centre that works closely with and is in regular contact with  community teams ensuring that patients and their carers receive specialist knowledge and advice to support individuals.

Contact
Location
Sheffield Institute for Translational Neuroscience, Glossop Road, Sheffield, UK

Specialists

Pamela Shaw

Professor of Neurology

Pamela Shaw is Professor of Neurology & Head of Neuroscience, University of Sheffield and Consultant Neurologist, Royal Hallamshire Hospital, where she established the Sheffield Care and Research Centre for Motor Neurone Disorders. She is Associate Director and Chair of the MND Clinical Studies Group for the UK Dementia and Neurodegenerative Diseases Clinical Research Network (DeNDRoN) and Academic Director of the Neuroscience Directorate at the Royal Hallamshire Hospital. She has received numerous awards and, most recently receiving the honour of Dame Commander of the Order of the British Empire (DBE) for services to neuroscience.

Pamela Shaw
Current trials
Recruiting
Phase iii

TUDCA-ALS (TUDCA)

Industry sponsored trial

TUDCA (tauroursodeoxycholic acid) is a small molecule that is being explored for its potential as a treatment for ALS

Read more
In preparation
Phase iii

PreLude (Lithium carbonate)

Platform trial

Within an innovative platform design study, we will evaluate the efficacy of lithium carbonate in UNC13a homozygous patients.

Read more
In preparation
Phase ii

Lighthouse (Triumeq)

Platform trial

Within an innovative platform design study, we will evaluate the efficacy of Triumeq, a therapy developed for treatment of HIV that has shown to slow progression in ALS

Read more
In preparation
Phase iii

iAdore (Oral edaravone)

Platform trial

Within an innovative platform design study, we will evaluate the efficacy of oral edaravone (TW001), a formulation that reduces oxidative stress

Read more